EGFR Tyrosine Kinase Inhibitor–Associated Interstitial Lung Disease During the Coronavirus Disease 2019 Pandemic

Saved in:
Bibliographic Details
Published inJournal of thoracic oncology Vol. 15; no. 8; pp. e129 - e131
Main Authors Chang, Hsu-Liang, Chen, Yen-Hsu, Taiwan, Hsin-Chu, Yang, Chih-Jen
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.08.2020
Copyright by the International Association for the Study of Lung Cancer
Published by Elsevier Inc. on behalf of International Association for the Study of Lung Cancer
Subjects
Betacoronavirus - isolation & purification
Coronavirus - isolation & purification
Coronavirus Infections - diagnosis
Coronavirus Infections - virology
COVID-19
Diagnosis, Differential
ErbB Receptors - antagonists & inhibitors
Humans
Lung Diseases, Interstitial - chemically induced
Lung Diseases, Interstitial - diagnosis
Lung Diseases, Interstitial - pathology
Lung Diseases, Interstitial - virology
Lung Neoplasms - drug therapy
Lung Neoplasms - enzymology
Pandemics
Pneumonia, Viral - diagnosis
Pneumonia, Viral - virology
Protein Kinase Inhibitors - adverse effects
Protein Kinase Inhibitors - therapeutic use
SARS-CoV-2
Online AccessGet full text

Cover

More Information
Bibliography:content type line 23
SourceType-Scholarly Journals-1
ObjectType-Correspondence-1
ISSN:1556-0864
1556-1380
1556-1380
DOI:10.1016/j.jtho.2020.04.029